Results 121 to 130 of about 264,442 (390)
Guideline‐directed medical therapy (GDMT) in patients with heart failure and reduced ejection fraction (HFrEF) reduces morbidity and mortality, but its implementation is often poor in daily clinical practice.
G. Savarese +28 more
semanticscholar +1 more source
To estimate the cost‐effectiveness of dapagliflozin added to standard therapy, vs. standard therapy only, in patients with heart failure (HF) with reduced ejection fraction (HFrEF), from the perspective of UK, German, and Spanish payers.
P. McEwan +8 more
semanticscholar +1 more source
AbstractAimPathophysiological differences between patients with heart failure with preserved (HFpEF) and reduced (HFrEF) ejection fraction (EF) remain unclear. Therefore we used a phenomics approach, integrating selected proteomics data with patient characteristics and cardiac structural and functional parameters, to get insight into differential ...
Van Essen, Bart J +20 more
openaire +4 more sources
The Treatment of Heart Failure with Reduced Ejection Fraction
Chronic congestive heart failure is a common condition that, if untreated, markedly impairs the quality of life and is associated with a high risk of recurrent hospitalization and death.This review is based on articles retrieved by a selective search in PubMed, as well as on relevant guidelines.Evidence-based treatment options are available only for ...
Dominik, Berliner +2 more
openaire +3 more sources
BLOC: Buildable and Linkable Organ on a Chip
We developed a “Buildable and Linkable Organ on a Chip” (BLOC) that can construct diverse microphysiological systems (MPSs). The BLOC is standardized to the same size and has one of the functions of “Culture,” “Control,” or “Analysis.” Users can freely configure various MPSs, including developing perfusion, cytotoxicity analysis, and biochemical ...
Yusuke Kimura +7 more
wiley +1 more source
Molecular Predictors of Anakinra Treatment Success in Heart Failure Patients with Reduced Ejection Fraction [PDF]
Background. Kineret (Anakinra) is an interleukin-1 antagonist that is under investigation for its novel clinical application treating patients that have heart failure with reduced (\u3c50%) ejection fraction (HFrEF).
Abbate, Antonio +13 more
core +1 more source
Efficacy profile of ivabradine in patients with heart failure plus angina pectoris [PDF]
Objectives: In the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT), slowing of the heart rate with ivabradine reduced cardiovascular death or heart failure hospitalizations among patients with systolic chronic heart ...
Borer, Jeffrey S. +9 more
core +1 more source
Fabrication, Properties, and Applications of Scaffolds for Bone Tissue Regeneration
This review explores cutting‐edge biomaterials and fabrication techniques for scaffolds in bone tissue regeneration. It conducts a critical comparison of various strategies, meticulously analyzes the key contradictions in the field, and outlines an integrated development path spanning from biomaterial selection to clinical application, while ...
Shangsi Chen, Min Wang
wiley +1 more source
Adaptive servo-ventilation for central sleep apnea in heart failure [PDF]
Background Central sleep apnea is associated with poor prognosis and death in patients with heart failure. Adaptive servo-ventilation is a therapy that uses a noninvasive ventilator to treat central sleep apnea by delivering servo-controlled inspiratory ...
Angermann, C +10 more
core +1 more source
High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction
Background: Small studies have suggested that high-intensity interval training (HIIT) is superior to moderate continuous training (MCT) in reversing cardiac remodeling and increasing aerobic capacity in patients with heart failure with reduced ejection ...
Ø. Ellingsen +27 more
semanticscholar +1 more source

